If a BRAF-mutated melanoma patient developed metastatic disease progression on adjuvant anti-PD-1 monotherapy, do you recommend switching to BRAF/MEK targeted therapy or combination nivolumab/ipilimumab?
Answer from: Medical Oncologist at Academic Institution
The developing pre-clinical and clinical data is clear on this and I believe it becomes even more clear with time. While the DREAMseq study did not enroll patients following adjuvant therapy as the patient in the case, the overall evidence clearly shows that BRAF/MEK inhibitor resistant melanomas ar...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
As mentioned by Dr. @Brent A. Hanks, there is no data in this setting as DREAMseq didn’t include patients who progressed on adjuvant anti-PD1. In my opinion, it depends on the nature of the progression. If it’s rapid and you think you only have one shot at controlling the disease, I...
Comments
Medical Oncologist at St Louis Cancer Care LLP
One of my BRAF mutated patients went through this ...
One of my BRAF mutated patients went through this ...
Medical Oncologist at Indiana University School of Medicine
That is great! How long has the patient been on BR...
That is great! How long has the patient been on BR...